PDCD1 and cancer: To overcome and reduce side effects and increase drug therapy efficacy, target-specific inhibitors/antibodies or immunotherapies (programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1)) have been used to treat several types of cancers [5, , -8]; however, more effective and safer anticancer drugs and supplemental alternatives are continuously needed.